SRPT
HEALTHCARESarepta Therapeutics Inc
$23.03+1.24 (+5.69%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SRPT Today?
No stock-specific AI insight has been generated for SRPT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.42$44.14
$23.03
Fundamentals
Market Cap$2.4B
P/E Ratio—
EPS$-7.13
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume4.8M
Avg Volume (10D)—
Shares Outstanding105.6M
SRPT News
21 articles- Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush SaysYahoo Finance·May 8, 2026
- Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?Yahoo Finance·May 7, 2026
- Sarepta tumbles as its gene therapy sales decline furtherBiopharmadive·May 7, 2026
- Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook MaintainedYahoo Finance·May 7, 2026
- Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.Yahoo Finance·May 7, 2026
- Sarepta Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Sarepta Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayYahoo Finance·May 6, 2026
- Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesYahoo Finance·May 6, 2026
- Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsYahoo Finance·May 6, 2026
- Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?Yahoo Finance·May 4, 2026
- Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance·Apr 29, 2026
- A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price VolatilityYahoo Finance·Apr 23, 2026
- Ocugen Stock Outlook: Valuation, Cash Runway and Dilution RiskYahoo Finance·Apr 22, 2026
- OCGN's Gene-Agnostic Strategy Could Reset Retinal TherapyYahoo Finance·Apr 22, 2026
- Sarepta Therapeutics to Announce First Quarter 2026 Financial ResultsYahoo Finance·Apr 22, 2026
- KROS 2026 Watchlist: 3 Catalysts That Could Reset SentimentYahoo Finance·Apr 20, 2026
- KROS Rinvatercept: What to Know Before DMD Phase II StartsYahoo Finance·Apr 20, 2026
- Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026Yahoo Finance·Apr 17, 2026
- Roche to start new Elevidys study following setback in EuropeBiopharmadive·Apr 16, 2026
- Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?Benzinga·Mar 27, 2026
All 21 articles loaded
Price Data
Open$22.12
Previous Close$21.79
Day High$23.49
Day Low$21.64
52 Week High$44.14
52 Week Low$10.42
52-Week Range
$10.42$44.14
$23.03
Fundamentals
Market Cap$2.4B
P/E Ratio—
EPS$-7.13
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume4.8M
Avg Volume (10D)—
Shares Outstanding105.6M
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—